SCHEMBL2365631

SCHEMBL2365631

CC1(C(=O)C(F)(F)F)CNCCc2cc(O)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.40
DRD1 P21728 2/20 0.40
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
ESR1 P03372 9/20 0.39
ESR2 Q92731 4/20 0.39
DRD4 P21917 2/20 0.36
DRD5 P21918 1/20 0.36
DRD3 P35462 1/20 0.36
ALDH1A1 P00352 3/20 0.35
CYP3A4 P08684 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 2/20 0.35
RECQL P46063 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
KDM4E B2RXH2 1/20 0.35
THRB P10828 1/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
CASP1 P29466 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16582899 0.85 DRD2 (0.44) DRD2DRD1HTR2AHTR2CESR1
SCHEMBL6653153 0.83 HTR2C (0.38) HTR2AHTR2CESR1ESR2
SCHEMBL6650634 0.82 ALDH1A1 (0.39) DRD2DRD1HTR2AHTR2CALDH1A1
SCHEMBL2477900 0.82 HTR2A (0.58) HTR2AHTR2C
SCHEMBL29051751 0.76 HTR2A (0.59) DRD2DRD1HTR2AHTR2CESR1
SCHEMBL6532681 0.75 HTR2C (0.49) DRD1HTR2AHTR2CDRD5
SCHEMBL2365900 0.73 HTR2A (0.51) HTR2AHTR2C
SCHEMBL6631310 0.72 FGFR4 (0.35) HTR2AHTR2CALDH1A1LMNAMAPT
Trifluoroacetic Acid SCHEMBL4915477 0.72 DRD2 (0.59) DRD2DRD1HTR2AHTR2CESR1
SCHEMBL1907864 0.72 ADRA2A (0.37) HTR2AHTR2CLMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575149-B2 5HT2C receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
EP-2363394-A1 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders Arena Pharmaceuticals, Inc. (US) 2011-09-07 EP disclosed